5//SEC Filing
Chan Andrew K 5
Accession 0001654954-19-001597
CIK 0001378624other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 9:53 PM ET
Size
19.2 KB
Accession
0001654954-19-001597
Insider Transaction Report
Form 5
Chan Andrew K
CFO and Secretary
Transactions
- Tax Payment
Common Stock
2018-05-27$17.10/sh−106$1,813→ 22,894 total - Tax Payment
Common Stock
2018-06-27$19.55/sh−106$2,072→ 22,788 total - Tax Payment
Common Stock
2018-07-27$20.60/sh−106$2,184→ 22,682 total - Tax Payment
Common Stock
2018-08-27$20.85/sh−106$2,210→ 22,576 total - Tax Payment
Common Stock
2018-09-27$22.00/sh−154$3,388→ 22,422 total - Sale
Common Stock
2018-10-26$12.75/sh−168$2,142→ 22,254 total - Sale
Common Stock
2018-11-27$18.07/sh−178$3,216→ 22,076 total - Sale
Common Stock
2018-12-27$17.64/sh−178$3,140→ 21,898 total
Footnotes (10)
- [F1]As previously reported on the Reporting Person's Form 4 filed on April 3, 2017, the Reporting Person was granted 23,000 restricted stock units ("RSUs") (Grant No. LTIP RSU G5) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan (the "Plan"), which RSUs vest over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
- [F10]The amount only includes shares of common stock granted as part of the Restricted Stock Units under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan and does not include any other shares of common stock of the issuer owned by the Reporting Person, the ownership of which has been reported in his prior filings pursuant to Section 16 of the Exchange Act.
- [F2]On May 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Friday, May 25, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
- [F3]On June 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Tuesday, June 26, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
- [F4]On July 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Thursday, July 26, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
- [F5]On August 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 106 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Friday, August 24, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
- [F6]On September 27, 2018, 479 RSUs vested and were delivered to the Reporting Person. Of the 479 RSUs that were vested and delivered, 154 shares of common stock were withheld (at the closing price of the Company's common stock on the NASDAQ Global Market on Wednesday, September 26, 2018) to satisfy the tax obligation relating to the vesting of the RSUs pursuant to Section 16b-3(e) under the Exchange Act.
- [F7]On October 26, 2018, upon vesting of his RSUs, the Reporting Person sold an aggregate of 168 shares of common stock at a per share price of $12.75. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
- [F8]On November 27, 2018, upon vesting of his RSUs, the Reporting Person sold an aggregate of 178 shares of common stock at a per share price of $18.07. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
- [F9]On December 27, 2018, upon vesting of his RSUs, the Reporting Person sold an aggregate of 178 shares of common stock at a per share price of $17.64. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
Documents
Issuer
Cellular Biomedicine Group, Inc.
CIK 0001378624
Entity typeother
Related Parties
1- filerCIK 0001569877
Filing Metadata
- Form type
- 5
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 9:53 PM ET
- Size
- 19.2 KB